Loading
A phase 3 trial of Alpelisib, Trastuzumab and Pertuzumab in HER2-positive breast cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation is a phase 3 interventional study registered as NCT04208178 by Novartis Pharmaceuticals, with 19 participants enrolled, started 2020-07-16 and due to reach its primary completion in 2027-02-26. Interventions recorded: Alpelisib, Alpelisib matching Placebo, Trastuzumab and Pertuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/